Menu
AZAD continually invests into further development and expansion of its FP portfolios. Development and validation of FPs is undertaken at EU-based contract manufacturers facilities under the direction of Azad`s pharmaceutical and regulatory specialists to produce CTD-format Dossiers, which are then out-licensed for customers to submit marketing authorization applications worldwide (ex-USA).
| Product | Therapeutic Indication | Status |
|---|---|---|
| Brinzolamide + Brimonidine, 10 mg/mL + 2 mg/mL, eye drops suspension, preservative-free | Treatment of Glaucoma | Under development |
| Brinzolamide, 10 mg/ml, eye drops suspension, preservative-free | Treatment of Glaucoma | Under development |
| Ferric Carboxymaltose, 50 mg/ml, concentrate for solution for infusion | Treatment of Iron Deficiency | Under development |
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.